@article{dfc06e4cd4da4997aed5b5d59aaace53,
title = "Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib",
abstract = "The 2016 WHO criteria identified early primary myelofibrosis (PMF) as an individual entity with milder clinical features and better outcome compared with overt PMF. Here, we compared early and overt PMF patients treated with ruxolitinib in terms of baseline clinical/laboratory characteristics, response, and toxicity to treatment. We observed that early-PMF patients achieve better and more stable spleen and symptoms responses, with significantly lower rates of hematological toxicities. No differences in overall and leukemia-free survival were detected between the two cohorts. The application of 2016 WHO criteria is crucial to identify those PMF patients who deserve a stricter monitoring during treatment. {\textcopyright} 2019 John Wiley & Sons, Ltd.",
keywords = "EARLY PMF, MYELOFIBROSIS, OVERT PMF, RUXOLITINIB, hemoglobin, ruxolitinib, antineoplastic agent, JAK2 protein, human, Janus kinase 2, protein kinase inhibitor, pyrazole derivative, tumor protein, adolescent, adult, aged, anemia, Article, bleeding, blood toxicity, bone marrow biopsy, cancer specific survival, clinical feature, clinical laboratory, clinical outcome, cohort analysis, female, heart disease, histology, human, infection, major clinical study, male, median survival time, myelofibrosis, myeloid metaplasia, overall survival, platelet count, priority journal, second cancer, splenomegaly, thrombocytopenia, treatment response, comparative study, differential diagnosis, early diagnosis, genetics, laboratory technique, middle aged, molecularly targeted therapy, organ size, pathology, retrospective study, spleen, thrombocythemia, treatment outcome, very elderly, World Health Organization, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Clinical Laboratory Techniques, Diagnosis, Differential, Early Diagnosis, Female, Humans, Janus Kinase 2, Male, Middle Aged, Molecular Targeted Therapy, Neoplasm Proteins, Organ Size, Primary Myelofibrosis, Protein Kinase Inhibitors, Pyrazoles, Retrospective Studies, Spleen, Thrombocythemia, Essential, Treatment Outcome",
author = "F. Palandri and G.A. Palumbo and E. Abruzzese and A. Iurlo and N. Polverelli and E. Elli and M. Bonifacio and M. Bergamaschi and B. Martino and M. Tiribelli and G. Benevolo and A. Tieghi and N. Sgherza and A. Isidori and G. Binotto and M. Crugnola and F. Heidel and F. Cavazzini and C. Bosi and G. Auteri and D. Cattaneo and R. Fo{\`a} and R.M. Lemoli and A. Cuneo and M. Krampera and D. Bartoletti and M. Cavo and N. Vianelli and M. Breccia and R. Latagliata",
note = "Export Date: 25 February 2020 CODEN: HAOND Correspondence Address: Palandri, F.; Institute of Hematology “L. and A. Ser{\`a}gnoli”, Sant'Orsola-Malpighi University HospitalItaly; email: francesca.palandri@unibo.it Chemicals/CAS: hemoglobin, 9008-02-0; ruxolitinib, 1092939-17-7, 941678-49-5; Antineoplastic Agents; INCB018424; JAK2 protein, human; Janus Kinase 2; Neoplasm Proteins; Protein Kinase Inhibitors; Pyrazoles References: Palandri, F., Latagliata, R., Polverelli, N., Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis (2015) Leukemia, 29 (6), pp. 1344-1349; Barbui, T., Thiele, J., Passamonti, F., Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: An international study (2011) J Clin Oncol, 29 (23), pp. 3179-3184; Vardiman, J.W., Thiele, J., Arber, D.A., The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes (2009) Blood, 114 (5), pp. 937-951; Harrison, C., Kiladjian, J.J., Al-Ali, H.K., JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis (2012) N Engl J Med, 366 (9), pp. 787-798; Verstovsek, S., Gotlib, J., Mesa, R.A., Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses (2017) J Hematol Oncol, 10 (1), p. 156; Arber, D.A., Orazi, A., Hasserjian, R., The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia (2016) Blood, 127 (20), pp. 2391-2405; Barbui, T., Tefferi, A., Vannucchi, A.M., (2018) Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet; Guglielmelli, P., Pacilli, A., Rotunno, G., Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis (2017) Blood, 129 (24), pp. 3227-3236; Thiele, J., Kvasnicka, H.M., Facchetti, F., Franco, V., van der Walt, J., Orazi, A., European consensus on grading bone marrow fibrosis and assessment of cellularity (2005) Haematologica, 90 (8), pp. 1128-1132; Tefferi, A., Cervantes, F., Mesa, R., Revised response criteria for myelofibrosis: International working group-myeloproliferative neoplasms research and treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report (2013) Blood, 122 (8), pp. 1395-1398; Palandri, F., Palumbo, G.A., Bonifacio, M., Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients (2018) Leuk Res, 74, pp. 86-88; Cervantes, F., Dupriez, B., Pereira, A., New prognostic scoring system for primary myelofibrosis based on a study of the international working Group for Myelofibrosis Research and Treatment (2009) Blood, 113 (13), pp. 2895-2901; Passamonti, F., Cervantes, F., Vannucchi, A.M., Dynamic international prognostic scoring system (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis (2010) Blood, 116 (15), pp. 2857-2858; Al-Ali, H.K., Stalbovskaya, V., Gopalakrishna, P., Perez-Ronco, J., Foltz, L., Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis (2016) Leuk Lymphoma, 57 (10), pp. 2464-2467; Palandri, F., Palumbo, G.A., Bonifacio, M., Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis (2017) Oncotarget, 8 (45), pp. 79073-79086; Polverelli, N., Breccia, M., Benevolo, G., Risk factors for infections in myelofibrosis: Role of disease status and treatment. A multicenter study of 507 patients (2017) Am J Hematol, 92 (1), pp. 37-41",
year = "2019",
month = oct,
day = "1",
doi = "10.1002/hon.2619",
language = "English",
volume = "37",
pages = "418--423",
journal = "Hematological Oncology",
issn = "0278-0232",
publisher = "wiley",
number = "4",
}